Description
The long awaited promise of
biosimilars takes another step to fulfilment with the first approval in Europe
of high-value second generation products. But what products can be expected to
follow, who is developing them and what are the hot prospects?
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/biosimilar-opportunities-in-an-evolving-market
Biosimilars: another milestone
passed
At the end of June 2013, the
European Medicines Agency’s Committee for Medical Products for Human Use issued
a positive opinion for the first biosimilar version of Johnson & Johnson’s
infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease
and plaque psoriasis. For the two successful applicants, Celltrion and Hospira,
this development passes a significant milestone for the whole biosimilar sector
as the products are the first monoclonal antibody (mAb) therapies to reach a
positive opinion following review via the EMA biosimilars regulatory pathway.
This is an important event which heralds a new era of lower-cost biological
therapies in Europe.
For J&J and its partners, the
news is less welcome. Already under pressure from branded competitors in the
TNF inhibitor market, it is no surprise that both developer and biosimilar
companies will be assessing what share they may secure of its US$6.13 billion
revenues.
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll Free:
866-997-4948
No comments:
Post a Comment